← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
Agilent grew again after the market reset, but cash flow and margins moved the wrong way.
The read at a glance✓ Audited against SEC data
- Growth — Revenue +6.7% to $6.95BOK
- Profitability — Operating margin -157 bps to 21.29%Watch
- Cash quality — FCF -16.1% to $1.15BWatch
- Segments — CrossLab $2.91B; LSDM $2.73BOK
- Capital — $282M dividends; $425M buybacksNote
- Balance sheet — Debt -8.8%; equity +14.3%OK
- Insiders — 0 buys / 6 sellsWatch
- Accounting — M-score clean; EQ 98.26 safeOK
Business
Agilent is a life sciences, diagnostics, and applied-markets company selling instruments, software, services, and consumables across laboratory workflows. In November 2024 it reorganized into Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets.
Where the revenue comes from
Fiscal 2025, as AGILENT TECHNOLOGIES, INC. reports it. History and quarterly detail are in the app.
- Agilent CrossLab$2.9B
- Life Sciences and Diagnostics Markets$2.7B
- Applied Markets$1.3B
Leadership changes
From AGILENT TECHNOLOGIES, INC.'s own filings, the day they're filed.
- Michael Buckner · Chief Legal Officer · departureeff. 2026-05-04
- Adam S. Elinoff · President · appointmenteff. 2025-11-17
- Rodney Gonsalves · Chief Financial Officer · appointmenteff. 2025-07-31
Latest filings
- 10-Q · Quarterly report2026-09-01
- 8-K · Company announcement2026-08-26
- 8-K · Company announcement2026-06-25
- 10-Q · Quarterly report2026-06-01
- 8-K · Company announcement2026-05-27
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about AGILENT TECHNOLOGIES, INC., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.